Benr alizumab for Hypereosinophilic Syndrome
H ypereosinophilic syndrome is a group of rare chronic disorders that are defined by an absolute eosinophil count (i.e., the number of eosinophils in blood) of at least 1500 cells per cubic millimeter and evidence of eosinophil-related clinical manifestations that can include intractable pruritus, pulmonary infiltrates, eosinophilic gastroenteritis, endomyocardial fibrosis, and thromboembolism. The goal of treatment is a reduction in blood and tissue eosinophilia, thereby preventing further organ damage. 1 Conventional therapies, including glucocorticoids and immunomodulatory and cytotoxic therapies, have variable efficacy and substantial toxic effects. 2 Despite promising early trial results with antibodies against interleukin-5, 3 ,4 the only therapy for this disorder that has been approved by the Food and Drug Administration (FDA) is imatinib mesylate, a tyrosine kinase inhibitor that is effective in the treatment of primary myeloid forms of the disease, including myeloid neoplasms associated with the gene encoding platelet-derived growth factor receptor alpha (PDGFRA) 5 ; new therapies that can help establish disease control in PDGFRA-negative hypereosinophilic syndrome are needed. 6 The interleukin-5 receptor is expressed on human eosinophils, their precursors, basophils, and mast cells. [7] [8] [9] [10] [11] Benralizumab (MEDI-563; Fasenra, MedImmune/AstraZeneca) is a humanized, afucosylated monoclonal antibody against interleukin-5 receptor α (IL5RA) that targets IL5RA-bearing cells for enhanced antibodydependent cellular cytotoxicity. 8 Benralizumab safely depleted eosinophils in the sputum and blood of patients with asthma. 12, 13 In phase 3 clinical trials involving patients with severe eosinophilic asthma, benralizumab reduced exacerbations and improved lung function. 14, 15 On the basis of these trials, in November 2017, the FDA approved the drug for use as add-on maintenance therapy for patients with severe eosinophilic asthma. Our current phase 2 trial was designed to assess the efficacy of benralizumab in reducing eosinophilia in patients with PDGFRAnegative hypereosinophilic syndrome.
Me thods

Patients
We used a protocol that was designed to evaluate patients with eosinophilia to screen adults with hypereosinophilic syndrome (ClinicalTrials.gov number, NCT00001406). A diagnosis of hypereosinophilic syndrome was determined by a history of persistent blood eosinophilia of at least 1500 cells per cubic millimeter without a known secondary cause and evidence of end-organ manifestations attributable to the eosinophilia. Symptomatic adults with a PDGFRA-negative hypereosinophilic syndrome and an absolute eosinophil count of at least 1000 cells per cubic millimeter while receiving stable therapy (drugs or dietary changes) for this disease for at least 1 month were eligible to participate in the trial. Full inclusion and exclusion criteria are provided in the Supplementary Appendix, available with the full text of this article at NEJM.org. Control samples for in vitro experiments were collected from healthy volunteers under protocols (NCT00090662; National Institutes of Health [NIH] protocol 93-CC-0094) that had been approved by institutional review boards at the NIH.
Trial Design
This single-center, investigator-initiated, phase 2 trial had three sequential stages: a randomized, double-blind, placebo-controlled phase (12 weeks) , an open-label phase (12 weeks) , and an openlabel extension phase (24 weeks) (Fig. 1A) . During the randomized phase, patients received benralizumab (at a dose of 30 mg) or placebo subcutaneously every 4 weeks for three doses while they were receiving stable therapy for hypereosinophilic syndrome. The trial team and patients were unaware of eosinophil counts during this phase. At week 12, all the patients began to receive subcutaneous injections of 30 mg of benralizumab every 4 weeks. From week 13 forward, the absolute eosinophil count was unblinded and background therapy was tapered, as tolerated. Patients who had a clinical or hematologic response at week 24 were eligible to continue to receive benralizumab during the openlabel extension. The trial-group assignments and eosinophil counts before week 13 were unblinded only after the last patient had completed the week 24 visit and the database had been locked.
Procedures and Outcome Measures
All clinical evaluations were performed at the NIH Clinical Center. After one of the patients in the benralizumab group (Patient 2) had a posttreatment reaction, the remaining patients were admitted for observation for at least 24 hours following the first dose of benralizumab or pla-T h e ne w e ngl a nd jou r na l o f m e dicine cebo and the first dose of open-label benralizumab (at week 12). Adverse events were scored at each visit with the use of the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4. Bone marrow aspirates and biopsy samples were obtained at baseline and at week 12. When possible, tissue biopsy samples were obtained at baseline and at week 24.
The primary end point was the percentage of patients who had a reduction of at least 50% in the absolute eosinophil count at week 12. Secondary end points included a reduction in the absolute eosinophil count at 12 weeks, the frequency and severity of adverse events, changes in bone marrow and tissue eosinophilia, and reductions in concomitant therapy at 48 weeks. Exploratory end points included an assessment of clinical and laboratory predictors of response. Details regarding trial procedures and end points are provided in the Supplementary Appendix.
Trial Oversight
The trial protocol, which was designed by the last author with input from coauthors, is available at NEJM.org and was approved by the institutional review board at the National Institute of Allergy and Infectious Diseases (NIAID). NIAID was the trial sponsor and obtained benralizumab under a cooperative research and development agreement with MedImmune/AstraZeneca. All the patients provided written informed consent.
Adverse events were reviewed every 6 months by an independent data and safety monitoring board. Representatives of the manufacturer who served as coauthors performed and analyzed the pharmacokinetic and antidrug-antibody assays (Fig. S6 in the Supplementary Appendix) but were not otherwise involved in data collection or drafting of the initial version of the manuscript. All the authors had full access to the data and vouch for the completeness and accuracy of the data and for the adherence of the trial to the protocol. All the authors reviewed the manuscript, and the first and last authors made the decision to submit the manuscript for publication.
Statistical Analysis
For the primary analysis, we used a two-sided Fisher's exact test to compare the percentages of patients who had a reduction of at least 50% in the eosinophil count in the two groups at 12 weeks. We determined that the enrollment of 10 patients in each group would provide a power of more than 90% to show a difference in the primary response, assuming a response rate of 1% in the placebo group and 70% in the benralizumab group. We performed analyses using the intention-to-treat principle in anticipation of few withdrawals on the basis of previous trials involving patients with this rare disease. Analyses for the secondary and exploratory end points are described in the Supplementary Appendix. . Three patients were excluded because they had an absolute eosinophil count of less than 1000 cells per cubic millimeter, and 1 was excluded because of unstable disease. Baseline demographic and clinical characteristics, including clinical disease subtype and end-organ involvement, were similar in the two groups ( Table 1, and Table S1 in the Supplementary Appendix). All the patients had not had an adequate response to a number of therapies (median number, 3.5; range, 1 to 11) and had shown a variety of clinical manifestations.
Efficacy
During the first 12 weeks of the trial, a reduction of at least 50% in the absolute eosinophil count at week 12 (the primary end point) occurred in more patients in the benralizumab group than in the placebo group (9 of 10 patients Patients 10 and 12 were identified as having had no response to treatment, so benralizumab was discontinued in these patients at weeks 16 and 24, respectively. Patients 1, 3, and 6 had a clinical and hematologic relapse after 12 to 24 weeks of response, which resulted in the discontinuation of benralizumab therapy. The remaining 14 of 19 patients (74%) continued to receive benralizumab through week 48 of the open-label phase and week 96 of the extension phase. On the basis of an assumption that Patient 17, who had withdrawn from the trial after receiving two doses of placebo, did not have a response, the median duration of response (≥50% reduction in the absolute eosinophil count) was 84 weeks (range, 0 to 96 weeks).
All 17 patients who had an initial hematologic response to benralizumab also reported having clinical improvement in their symptoms.
(Clinical vignettes are provided in the Supplementary Appendix, and photographs of a patient before and after therapy are shown in Fig. 2A .) Concomitant therapies other than benralizumab were tapered on the basis of absolute eosinophil counts and clinical manifestations beginning at * There was no significant difference between the two groups. † Some patients were receiving more than one agent for background therapy. ‡ The two patients with myeloid variant disease had genetic changes in JAK2 (one with the V617F mutation and one with a complex insertion or deletion in exon 13 [codon 583-586]). The numbers of bone marrow eosinophils, eosinophil precursors, and blood and bone marrow basophils were significantly decreased at week 12 in all the patients in the benralizumab group, but the number of mast cells and serum tryptase levels were unchanged (Fig. 3, and Fig.  S3 in the Supplementary Appendix). Tissue samples obtained at week 24 showed nearly complete depletion of eosinophils (≤1 eosinophil per high-power field) in a total of 52 gastrointestinal biopsy samples obtained from the seven patients with gastrointestinal eosinophilia (Table  S3 in the Supplementary Appendix). Immunohistochemical staining for eosinophil peroxidase (anti-EPX) confirmed the absence of tissue eosinophils and eosinophil granules in samples obtained from two patients (Fig. 2B) . Bronchoalveolar lavage that was performed at baseline and at week 24 in a patient with a history of eosinophilic pulmonary infiltrates (Patient 9) showed resolution of bronchoalveolar lavage eosinophilia while the patient was receiving benralizumab therapy (data not shown). Patients 4 and 19, who had previous evidence of eosinophilia in skin-biopsy samples, underwent repeated biopsy during the course of the trial to evaluate new or worsening rash. Eosinophils were absent in both biopsy samples obtained during benralizumab therapy, and the rash resolved in the two patients.
Safety
A total of 238 adverse events were reported during the randomized phase of the trial; the number of adverse events (including grade 3) and the number of patients reporting an adverse event were similar in the two groups ( Table 2 ). The only serious adverse event (hypotension) occurred in a patient receiving placebo. Six patients in the benralizumab group had transient, mild lymphocytopenia after the first dose, and persistent lymphocytopenia developed in one patient in the placebo group (P = 0.06).
Adverse events that were deemed by investigators to be possibly, probably, or definitely related to benralizumab during the entire 48 weeks of the trial are listed in Table S4 in the Supplementary Appendix. No deaths were reported, and no patient discontinued benralizumab because of an adverse event. Two grade 3 serious adverse events were deemed to be possibly related to benralizumab: eosinophilia that occurred after discontinuation of the drug (because of a lack of response) in Patient 10 and ureteral obstruction from a kidney stone in Patient 2, who had an elevated serum uric acid level. Serum uric acid levels were monitored every 3 months for 1 year and yearly thereafter in subsequent patients and were in the normal range in all the patients tested.
Eight patients had a constellation of symptoms, including fever, chills, headache, nausea, and fatigue, approximately 6 hours after the first dose of benralizumab (Table S5 in the Supplementary Appendix). These self-limited episodes did not recur with subsequent doses. Serum lactate dehydrogenase levels increased in 16 of 19 patients on the day after the first dose of benralizumab; a greater increase was observed in patients who had post-injection reactions than in those who did not (median increase, 72 ng per milliliter and 12 ng per milliliter, respectively; P = 0.006). None of the variables that were examined, which included the clinical disease Panel A shows a 37-year-old woman with a lymphoid form of hypereosinophilic syndrome before and after treatment with benralizumab. At baseline, the patient's severe spongiotic dermatitis was complicated by superinfections and bacteremia, resulting in multiple hospitalizations. Previous therapies included oral prednisone (40 mg daily), phototherapy, methotrexate, cyclosporine, mycophenolate, thalidomide, interferon alfa, and various topical agents, none of which adequately controlled her symptoms or eosinophilia. The baseline eosinophil count was 1650 cells per cubic millimeter while the patient was receiving subcutaneous pegylated interferon alfa (90 μg weekly). Since she had been assigned to the placebo group, she did not receive benralizumab until week 12 during the open-label phase of the trial. At week 13, the eosinophil count had dropped to 30 cells per cubic millimeter and declined further to 0 cells per cubic millimeter by week 15. After three monthly doses of benralizumab, during which the pegylated interferon alfa was discontinued, there was a great reduction in the number of skin lesions and associated infections. (A more detailed case vignette about this patient is provided in the Supplementary Appendix.) Panel B shows representative gastric and colonic biopsy samples (hematoxylin and eosin staining and immunostaining against eosinophil peroxidase [anti-EPX]) obtained from two patients with eosinophilic gastrointestinal disorders (Patients 7 and 13) at baseline (top row) and after benralizumab therapy at week 24 (bottom row). In the two patients, biopsy samples showed an eosinophil count of more than 200 cells per high-power field at baseline and a count of 0 at week 24.
T h e ne w e ngl a nd jou r na l o f m e dicine subtype, baseline therapy, pretreatment numbers of eosinophils and natural killer (NK) cells, and the activation status of NK cells, were associated with the development of post-treatment reactions (Table S6 in the Supplementary Appendix).
Although this trial was not designed to explore the long-term effects of eosinophil depletion in humans, exploratory studies in the benralizumab group revealed no evidence of impaired recall response to tetanus vaccination (in 14 patients) or altered glucose metabolism as assessed by measurement of the glycated hemoglobin level (in 19 patients).
Factors Associated with Clinical Outcomes
The 2 patients who did not have a response to benralizumab had received the diagnosis of a primary myeloid hypereosinophilic syndrome Since benralizumab action depends on the activity of NK cells, we assessed the number of NK cells, the ratio of NK cells to eosinophils in whole blood, and CD16 polymorphisms associated with altered efficiency of NK-mediated antibody-dependent cellular cytotoxicity. At baseline, we quantified benralizumab-induced NK-mediated killing of eosinophils in vitro using autologous eosinophils and NK cells. None of these measurements appeared to be associated with an initial clinical response or relapse (Fig. S5 in the Supplementary Appendix).
no. no. (%) no. no. (%)
Serious adverse event Any 0 1 1 (10) Hypotension 0 1 1 (10) Adverse event Any grade 124 10 (100) 114 10 (100) Grade 1 79 9 (90) 68 7 (70) Grade 2 37 10 (100) 34 10 (100) Grade 3 8 6 (60) 12 5 (50) Grade 4 0 0 Grade 3 adverse event Fatigue 3 3 (30) 1 1 (10) Hyponatremia 3 2 (20) 0 Abdominal pain 1 1 (10) 1 1 (10) Headache 1 1 (10) 0 Eosinophilia 0 5 3 (30ne w e ngl a nd jou r na l o f m e dicine with a JAK2 mutation. All 3 patients who had a relapse after
Drug Levels and Antidrug Antibodies
In most of the patients, all measured serum trough levels of benralizumab were within the 90th prediction interval on the basis of the Monte Carlo simulation 16 derived from the nine clinical trials of benralizumab involving patients with asthma (Fig. S6A, S6B , and S6C in the Supplementary Appendix). Of the 3 patients who had a relapse, 2 (Patients 1 and 6) had declining drug-trough levels at the time of relapse (Fig.  S6D in the Supplementary Appendix). The third patient who had a relapse (Patient 3) had undetectable drug trough levels at all time points and measurable antidrug antibodies with rising titers after the third dose of benralizumab, a finding that coincided with relapse. Of the 19 patients who received benralizumab, 3 had detectable antidrug antibodies after receiving the drug; of these patients, 2 (Patients 3 and 9) also had decreased serum drug trough levels (Fig. S6E in the Supplementary Appendix). The frequency of antidrug-antibody development in our trial was similar to that in patients with asthma who had received the same benralizumab regimen. 14, 15, 17, 18 
Discussion
In this small phase 2 trial involving a diverse group of patients with PDGFRA-negative hypereosinophilic syndrome with persistent disease or severe side effects after receiving multiple previous therapies, the percentage of patients who had a hematologic and clinical response to benralizumab therapy was 74% at week 48. This observed response rate is similar to those reported for glucocorticoid 2 and mepolizumab 3, 19, 20 treatment of this disorder. During the 12-week randomized phase of the trial, three patients in the placebo group met the primary end point of a reduction of at least 50% in the absolute eosinophil count. In one of these patients (Patient 8), the improvement was related to the timing of pulsed cyclophosphamide therapy in relation to the trial time points. The reasons for the decreased absolute eosinophil counts in the other two patients are unclear, although neither had resolution of eosinophilia or symptomatic improvement while receiving placebo. In contrast to eosinophils, which were undetectable in the blood, bone marrow, and tissues after 12 weeks of benralizumab therapy, basophils were reduced in numbers but were not absent in the peripheral blood and bone marrow, and the numbers of mast cells in bone marrow were unchanged. Although the relative contributions of these effector cells to allergic manifestations are controversial, 21 it is noteworthy that benralizumab-treated patients continued to have chronic urticaria, seasonal allergies, and immediate hypersensitivity reactions to food, despite resolution of clinical manifestations of hypereosinophilic syndrome. (Clinical vignettes describing such patients are provided in the Supplementary Appendix.) Whether these reactions were due to the persistence of basophils and mast cells in the blood and tissues is unknown.
As in the trials involving patients with asthma, benralizumab was associated with few side effects in this trial. Mild or moderate post-treatment reactions occurred in eight patients after the first dose of benralizumab, but symptoms were transient and did not lead to drug discontinuation. Clinically similar reactions were reported in a small number of patients participating in early trials of intravenous benralizumab 12, 13 but were absent in subsequent studies with subcutaneous administration. 14, 15, 17, 18 The most likely mechanism of the observed post-treatment reactions is eosinophil killing mediated by antibodydependent cellular cytotoxicity, given the timing and nature of the symptoms, the presence of elevated lactate dehydrogenase levels, and a lack of other explanations (e.g., no change in serum tryptase levels, which would indicate a mast-cellmediated process). An alternative explanation is cytokine release by activated NK cells, which has been reported with rituximab. 22 Of the many clinical and laboratory measurements that we examined, only the clinical disease subtype appeared to be associated with the clinical response. Differing response rates among patients with clinical subtypes of this disorder have also been described for glucocorticoids, 23 imatinib, 5 and mepolizumab, 19, 20 which suggests that the mechanism driving the eosinophilia plays an important role in the therapeutic response. The sustained response in Patient 15, who had a lymphoid hypereosinophilic syndrome with an aberrant CD3−CD4+ T-cell population, suggests that clinical disease subtype is not the sole determinant of response. However, Patient 3, who had a relapse, also had a lymphoid form of the disease, high serum levels of soluble IL5RA, and the development of antidrug antibodies, findings that are consistent with the hypothesis that response is multifactorial.
Limitations of this trial include the small sample size and lack of validated clinical outcome measures for this rare disease. The purposeful inclusion of a diverse group of patients with varied disease manifestations allowed us to explore the role of clinical subtype in the response to therapy. However, this heterogeneity also made it more difficult to find a common clinical outcome measure to assess efficacy. Finally, the small number of patients who did not have a response precluded any definitive conclusions with respect to predictors of response to benralizumab.
Despite these limitations, the trial showed that benralizumab therapy is effective in reducing blood and tissue eosinophilia with few or no toxic effects in patients with severe, treatmentrefractory hypereosinophilic syndrome, despite having markedly higher eosinophil levels than patients with asthma. Equally important for this chronic and debilitating disorder, the eosinophillowering effect of benralizumab was sustained in the majority of patients despite tapering of other therapies that have substantial long-term toxic effects. A larger, well-controlled, multicenter trial of benralizumab is clearly needed to confirm these results and further explore the role of clinical disease subtype and other factors in the treatment response in patients with hypereosinophilic syndrome. Dr. Lee reports being employed by MedImmune; Dr. Kolbeck, being employed by MedImmune and owning shares of stock in AstraZeneca; Dr. Newbold, being employed by and holding stock in AstraZeneca; and Dr. Goldman, being employed by AstraZeneca. No other potential conflict of interest relevant to this article was reported.
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